Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide plus 2 NRTIs versus efavirenz plus 2 NRTIs in ART-naive HIV patients with tuberculosis
ChiCTR2200062461Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Southern University of Science and Technology
- Start
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of albuvirtide in Human immunodeficiency virus infection type 1 and pulmonary tuberculosis (TB) (2 arms), sponsored by The Second Affiliated Hospital of Southern University of Science and Technology. Primary endpoint: Plasma HIV-1 RNA. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
albuvirtide
03
Conditions
Human immunodeficiency virus infection type 1pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2200062461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062461.